Valuation: Opus Genetics, Inc.

Market Cap 31Cr 26Cr 25Cr 23Cr 42Cr 2.93TCr 43Cr 290.15Cr 113.62Cr 1.47TCr 115.27Cr 112.76Cr 4.87TCr P/E 2026 *
-3.73x
P/E 2027 * -5.23x
Enterprise Value 31Cr 26Cr 25Cr 23Cr 42Cr 2.93TCr 43Cr 290.15Cr 113.62Cr 1.47TCr 115.27Cr 112.76Cr 4.87TCr EV / Sales 2026 *
22.8x
EV / Sales 2027 * 21.3x
Free-Float
89.06%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Opus Genetics, Inc.

1 day+10.30%
1 week+8.24%
Current month+9.70%
1 month+33.44%
3 months-4.46%
6 months+14.01%
Current year+102.49%
1 week 3.55
Extreme 3.55
4.08
1 month 2.82
Extreme 2.82
4.08
Current year 1.88
Extreme 1.88
5.81
1 year 1.11
Extreme 1.11
5.81
3 years 0.65
Extreme 0.65
5.81
5 years 0.65
Extreme 0.65
6.6
10 years 0.65
Extreme 0.65
13.81
Manager TitleAgeSince
Chief Executive Officer 42 01/11/2023
Director of Finance/CFO 52 02/09/2025
President 60 22/10/2024
Director TitleAgeSince
Director/Board Member 77 01/11/2020
Chairman 56 01/12/2019
Director/Board Member 59 01/11/2020
Date Insider Type Main position Quantity % Market Cap.
23/07/26 Sell

Chief Financial Officer

-7,783 0.0094%
23/07/26 Sell

Chairperson

-7,429 0.0090%
23/07/26 Sell

Chief Executive Officer

-9,475 0.0115%
Change 5-day change 1-year change 3-year change Capi.($)
+10.30%+8.24%+266.67%+0.99% 31Cr
+4.46%+4.92%+82.07%+132.77% 1,09300Cr
+0.85%+4.81%+53.77%+63.38% 65TCr
+2.72%+6.92%+28.99%+77.12% 46TCr
+1.80%-0.41%+43.52%+44.05% 35TCr
+1.24%+1.00%+26.84%+42.21% 29TCr
+2.07%+1.74%+2.66%+13.06% 25TCr
+4.02%+6.29%+49.67%+69.68% 23TCr
+1.05%-2.52%-13.83%-52.13% 20TCr
+2.90%+8.63%+25.11%+94.36% 18TCr
Average +2.93%+0.59%+56.55%+48.55% 37.11TCr
Weighted average by Cap. +2.44%+1.45%+47.21%+74.17%

Financials

2026 *2027 *
Net sales 1.34Cr 1.15Cr 1.08Cr 98.74L 1.86Cr 128.42Cr 1.89Cr 13Cr 4.97Cr 64Cr 5.04Cr 4.94Cr 212.95Cr 1.44Cr 1.23Cr 1.15Cr 1.06Cr 1.99Cr 137.57Cr 2.02Cr 14Cr 5.33Cr 69Cr 5.4Cr 5.29Cr 228.13Cr
Net income -9.27Cr -7.95Cr -7.42Cr -6.81Cr -13Cr -885.83Cr -13Cr -88Cr -34Cr -444.27Cr -35Cr -34Cr -1.47TCr -6.82Cr -5.85Cr -5.46Cr -5.01Cr -9.42Cr -651.52Cr -9.58Cr -64Cr -25Cr -326.76Cr -26Cr -25Cr -1.08TCr
Net Debt - -
Logo Opus Genetics, Inc.
Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.
Employees
28
Date Price Change Volume
20/26/20 $4.070 +10.30% 7,30,431
18/26/18 $3.690 +1.10% 7,52,875
17/26/17 $3.650 +1.11% 6,08,374
14/26/14 $3.610 -2.96% 4,14,480
13/26/13 $3.720 -1.06% 5,13,353
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
3.690USD
Average target price
10.61USD
Spread / Average Target
+187.56%

Quarterly revenue - Rate of surprise